Dr. Andreas Ladurner
Chair
pharmaceutical
VolitionRx
Singapore
Biography
Dr. Andreas Ladurner has been Chair of Physiological Chemistry in the Faculty of Medicine of the Ludwig-Maximilians-University of Munich (LMU) since 2010. His team’s research focuses on the molecular mechanisms of chromatin plasticity and gene-environment interactions. Prior to joining LMU, Dr. Ladurner was Group Leader in the Genome Biology Unit of the European Molecular Biology Laboratory in Heidelberg. During this period, Dr. Ladurner discovered the histone variant technology that is an integral part of the Nucleosomics® technology which Volition is developing. Before joining EMBL, Dr. Ladurner was Editor at the Nature Publishing Group in New York and Research Associate of the Howard Hughes Medical Institute at the University of California at Berkeley, as well as recipient of the Wellcome Trust International Prize. Ladurner received his B.Sc. from the University of York in 1994, worked as a scientist at SmithKline Beecham (now Glaxo SmithKline) and obtained his PhD from the University of Cambridge in 2000.
Research Interest
Physiological Chemistry
